Brainsway reports independent pilot data on Deep TMS technology for AUD

BrainsWay (BWAY) announced recent positive pilot data from an independent, third-party study conducted at Stanford University evaluating an accelerated protocol using the Company’s Deep Transcranial Magnetic Stimulation, TMS, technology to treat alcohol use disorder, AUD, patients. The outcomes were reported in a publication in the Brain Stimulation journal entitled, “Accelerated deep TMS in alcohol use disorder: A preliminary pilot trial targeting the dorsal anterior cingulate cortex increases neural target engagement and abstinence.” In the follow-up period after treatment, subjects receiving accelerated Deep TMS showed notably better improvements when compared to those treated by other means. The better outcomes were seen in several important areas, including lower percentages of heavy drinking days and regular drinking days, as well as lower relapse rates